Production of transgenic cattle by somatic cell nuclear transfer (SCNT) with the human granulocyte colony-stimulation factor (hG-CSF)

Bruno P. Carvalho¹, Andrielle T. M. Cunha¹, Bianca D. M. Silva², Regivaldo V. Sousa², Ligiane O. Leme³, Margot A. N. Dode¹,² and Eduardo O. Melo²,⁴*

¹Institute of Biology, Universidade de Brasília, Brasilia-DF, 70910-900, Brazil
²Laboratory of Animal Reproduction, Embrapa Genetic Resources and Biotechnology, Brasília-DF, 70770-917, Brazil
³Department of Veterinary Medicine, Universidade Federal do Espírito Santo, Alegre-ES, 29500-000, Brazil
⁴Department of Biotechnology, Universidade Federal do Tocantins, Gurupi-TO, 77402-970, Brazil

Abstract
The hG-CSF (human Granulocyte Colony-Stimulating Factor) is a growth and stimulation factor capable of inducing the proliferation of bone marrow cells, several types of leukocytes, among other hematopoietic tissue cells. hG-CSF is used in used to treat anomalies that reda a small number of circulating white blood cells, which may compromise the immune defenses of the affected person. For these reasons, the production of hG-CSF in a bioreactor system using the mammary gland of genetic modified animals is a possibility of adding value to the bovine genetic material and reducing the costs of hG-CSF production in pharmaceutical industry. In this study, we aimed the production of transgenic hG-CSF bovine through the lipofection of bovine primary fibroblasts with an hG-CSF expression cassette and cloning these fibroblasts by the somatic cell nuclear transfer (SCNT) technique. The bovine fibroblasts transfected with the hG-CSF cassette presented a stable insertion of this construct into their genome and were efficiently synchronized to G0/G1 cell cycle stage. The transgenic fibroblasts were cloned by SCNT and produced 103 transferred embryos and 2 pregnancies, one of which reached 7 months of gestation.

Keywords: Biotechnology, Genetically modified organisms, Leukopenia, Lipofection

Background
G-CSF (Granulocyte Colony-Stimulating Factor), together with GM-CSF (granulocyte-macrophage colony stimulating factor) and M-CSF (macrophage colony stimulating factor), are members of the CSF (colony stimulating factor) family. This family of growth factors (or cytokines) was first described for its ability to stimulate in vitro the proliferation of immune cells such as granulocytes and macrophages [1]. Granulocytes are composed of four cell types of the immune system: Basophils, Eosinophils, Neutrophils and Mast cells. They are produced in the bone marrow where they undergo differentiation in their subtypes and go to the bloodstream (with the exception of the mast cells), where they will constitute most of the so-called white blood cells that are responsible for the immune defense of our body [1,2]. G-CSF binds to the surface of responsive cells through a homo-dimeric transmembrane receptor designated...
G-CSF-R (also known as CD114). This binding causes activation of the intracellular domain of the receptor with a kinase activity capable of phosphorylating and activating various intracellular signals such as the Jak-Stat (Janus kinase - Signal Transducer and Activator of Transcription protein), MapK1/2 (mitogen-activated protein kinase 1 and 2) and PI3K (phosphatidylinositol 3-kinase) family [2,3]. The family activated will depend on the cell type and physiological condition of the responsive cells, which can be bone marrow cells, various types of leukocytes, cancer cells and nerve cells, among others. Activation of the intracellular signaling cascades by G-CSF provokes, among other effects, the stimulation for cell proliferation [3]. Leukopenia is an anomalous state where is a small number of circulating white blood cells, which can compromise the immune defenses of the patient with this condition. Leukopenia can be caused by a number of factors: genetic abnormality, bone marrow transplant, some types of cancer, treatment with radiation therapy and chemotherapy, viral infections, among other conditions [2]. One of the alternatives for treating leukopenia is to increase circulating granulocyte levels using purified G-CSF in biopharmaceutical applications [4]. Due to its applications in medicine, human G-CSF (human Granulocyte Colony-Stimulating Factor, hG-CSF) has a high added value, with an annual $5 billion market only in the United States, which make it an interesting candidate to be produced in bioreactors [2,5]. G-CSF, as well as any biologically complex molecule expressed by mammals, undergoes post-translational modifications that may change their biological activity in either prokaryotic (bacteria) or simple eukaryotic (fungi and yeast) production systems. Therefore, the production of its most human-similar form is frequently achieved in genetic modified mammalian-cell culture system in vitro [6]. However, this platform for production of biomolecules is of high cost and low efficiency, and more efficient production alternatives such as the mammary gland have been advocated in recent years by various research groups and institutes around the world [5,7]. Therefore, the production of biomolecules of biotechnological interest in animal models is of high biotechnological interest and if the platform is a dairy animal, it is of interest to the agricultural sector as well. In this study, we aimed the production of transgenic hG-CSF bovine through the lipofection of bovine primary fibroblasts with an hG-CSF expression cassette and cloning these fibroblasts by the somatic cell nuclear transfer (SCNT) technique.

Material and Methods

All reagents used in this study are purchased from Sigma-Aldrich (São Paulo, Brazil), unless specified.

**G-CSF expression cassette**

The cassette with the β-casein (bovine) promoter and the hG-CSF gene was obtained by digestion of the vector pCR2.1-hG-CSF, kindly provided by the RDA (Rural Development Agency, South Korea), with the enzyme Not I. The electrophoresis of the products of this digestion produced two DNA fragments (4.8 kb of the G-CSF cassette and 5.5 kb of the pCR2.1 vector, Invitrogen). The 4.8 kb fragment were purified from the gel using the Wizard SV Kit (Promega, Fitchburg, WI, USA). The G-CSF cassette was cloned into the Not I site of the pcDNA vector (Promega) by the enzyme T4 DNA Ligase (Promega), following the manufacturer’s recommendations (supplementary Fig. S1). The binding system was transformed into *E. coli* DH5α by thermal-shock transformation [8]. Ampicillin-resistant (100 η g/mL) colonies had their plasmid DNA extracted by the salting-out method [9]. The isolated clones were confirmed by digestion with the Eco RI enzyme (Promega) which has the ability to discriminate the pcDNA vector with the insert and its correct orientation. The final construct (pcDNA-G-CSF) was confirmed by DNA sequencing (Helixxa Genomic Services S.A., São Paulo Brazil).

**Isolation and culture of bovine skin fibroblasts**

Fibroblasts were isolated from a biopsy obtained from the skin of a 4 years old female Holstein and cultured in vitro according to protocols already established in the Laboratory of Animal Reproduction of Embrapa Genetic Resources and Biotechnology [10]. The isolated cells were cultured in DMEM medium (Gibco BRL, Billings, MT, USA) enriched with 10% fetal bovine serum (FBS) to the 2nd cell pass and frozen in culture medium containing 10% Dimethylsulfoxide (Sigma, Marlborough, MA, USA), in 0.25 mL vials and stored in liquid nitrogen. Such stock cells were used throughout this work to provide the fibroblasts for insertion of the genes of interest and thereafter as nucleus donors in the TNCS procedures.

**Bovine fibroblasts transfection**

Bovine fibroblasts of primary origin, obtained from LRA from skin biopsies, were cultured in vitro (with D-MEM medium + 10% FBS) at 38°C in humidified incubator. These cells were transfected with the DNA fragment containing the hG-CSF cassette and the Neo gene, removed from the pCiNeo-G-CSF vector with Sac I and Bam HI enzymes (Promega). The 6,800 bp fragment containing the G-CSF cassette and the Neomycin/G418 resistance gene (NeoR) was purified from agarose gel (0.8%) with Wizard-SV Kit (Promega), quantified by spectrophotometry and confirmed by agarose gel staining. On the day prior to transfection, 200,000 to 250,000 fibroblasts were seeded into 24 well plates and allowed to adhere to the bottom so that the next day they reached 60%–80% confluence of the well area. In transfections, 0.25 η g of the pEF-GFP (green fluorescent protein) vector (Addgene, Cam-
Involves the removal of a small portion of cytoplasmic material by a micromanipulator (Eppendorf, Hamburg, Germany). The process was performed under a Nikon inverted microscope (Nikon, Tokyo, Japan), with the aid of a TransferMAN NK2 electronic micromanipulator (Eppendorf, Hamburg, Germany). Before enucleation (removal of nuclear DNA) the oocytes were incubated for 20 minutes with 2 μg/mL DNA dye Hoechst 33342 and 3.33 μg/mL cytochalasin D, diluted in maturation medium. The enucleations were performed under a Nikon inverted microscope (Nikon, Tokyo, Japan), with the aid of a TransferMAN NK2 electronic micromanipulator. The process involves the removal of a small portion of cytoplasmic material accompanied by the metaphase plate adjacent to the first polar corpuscle, confirmed by visualization under UV light of the DNA stained with Hoechst 33342. During reconstruction, the donor cells of the genomic DNA (transgenic fibroblasts) were inserted into the perivitelline space. The karyoplast complexes were positioned between two parallel electrodes with fusion medium and received DC pulses of 2.5 kV/cm, generated by the BTX-ECM 200 electrofusion apparatus (Harvard Apparatus, Inc., Holliston, MA, USA). After fusion, the karyoplast complexes were artificially activated using 5 μM Ionomycin prepared in SOFaci [13] with addition of FBS followed by incubation with 2 mM 6-dimethylaminopurine (6-DMAP) prepared in synthetic oviductal fluid (SOF) with addition of FBS.

**Oocyte collection and in vitro maturation**

The bovine ovaries used were collected at slaughterhouse and the follicles measuring from 3 to 8 mm were aspirated with the aid of a 19G needle connected to a vacuum system. The oocytes collected were classified based on the cumulus cell layer and homogeneity of the cytoplasm, and placed in 200 μL drops of in vitro maturation medium, consisting of 199 medium (Invitrogen), supplemented with 10% FBS (Invitrogen), 10 μg/mL FSH (follicle stimulating hormone), 100 IU/mL penicillin and 50 μg/mL streptomycin, covered with mineral oil and kept in incubator at 37°C, 5% CO₂ and saturated humidity.

**Cloning of somatic cells by nuclear transfer (SCNT)**

The SCNT employed in our study was performed as described in the literature [11], with some modifications described previously by our group [12]. After the maturation period, the oocytes were denuded in 0.2% hyaluronidase and selected according to the expulsion of the first polar corpuscle and cytoplasmic quality. Before enucleation (removal of nuclear DNA) the oocytes were incubated for 20 minutes with 2 μg/mL DNA dye Hoechst 33342 and 3.33 μg/mL cytochalasin D, diluted in maturation medium. The enucleations were performed under a Nikon inverted microscope (Nikon, Tokyo, Japan), with the aid of a TransferMAN NK2 electronic micromanipulator (Eppendorf, Hamburg, Germany). The process involves the removal of a small portion of cytoplasmic material.

**In vitro culture and anovulation of SCNT embryos**

The reconstructed karyoplast complexes were co-cultured in 9.2 cm² Petri dishes (Corning, Midland, Michigan, USA) over a layer of bovine granulosa cells in 160 μL drops of SOFaci medium supplemented with 5% FBS, covered with silicone oil, and kept in humidified incubators at 39°C 2 and saturated humidity. The development rate were checked on day 2 for evaluation of cleavage, and day 7 for evaluation of blastocyst rate. Nellore heifers were used as recipients for the SCNT embryos. Prior to the embryo transfer, they were submitted to a fixed-time embryo transfer synchronization protocol, which consists of placement of an intra-vaginal implant containing 1 g of progesterone (day 0 –D0) and an i.m. injection of 2 mg of estradiol benzoate in D5, 150 μg of PGF2α (prostaglandin alfa) was i.m. injected in D8, the progesterone implant was withdrawn in D9 and 1 mg of estradiol benzoate was injected before blastocyst embryos were transferred. On the day of the transfer the recipients were evaluated for location and classification of the corpus luteum size as class I, II, III (large, medium and small respectively). In those who were able to receive the embryo (class I and II), epidural anesthesia was performed with 3 mL of 2% lidocaine hydrochloride in the sacro-coccix space to relax the pelvic region. For anovulation, an applicator was used by inserting the vial containing the embryo and depositing the embryos in the ipsilateral horn to the corpus luteum. After 30, 60, and 90 days after embryo transfer, transverse rectal ultrasonography (Aloka SSD-500, Overseas Monitor Corporation, Richmond, BC, USA) with a 7.5 MHz linear transducer as used to evaluate pregnancy and follow-up the fetal development. Rectal palpation was also used to assess the texture of the placenta, as well as the number and distribution of the placentomes.

**Embryo vitrification and warming**

Embryo vitrification was performed as previously described by [14], with minor modifications. A holding medium (HM) was used to...
handle embryos during vitrification and warming procedures, and was composed of HEPES buffered TCM-199 (Invitrogen®) supplemented with 20% FBS. For vitrification, the groups of embryos were first washed three times in an equilibrium solution composed of 7.5% ethylene glycol (EG) and 7.5% dimethyl sulfoxide (ME2SO) dissolved in HM for a minimum of 9 minutes. Embryos were then transferred to a vitrification solution consisting of 15% EG, 15% ME2SO, and 0.5 M sucrose in HM, and incubated for 45 to 60 seconds. Next, embryos were placed in a Cryotop® device (Kitazato Corp., Japan) in sets of 3 to 5 embryos under a stereomicroscope. Subsequently, the Cryotop® was immediately submerged in liquid nitrogen. The vitrified embryos were stored in the liquid nitrogen container, until an adequate moment for transfer into hormone-synchronized female recipients. At that time, warming was performed by immersing the end of the Cryotop® for 1 minute in a drop of HM supplemented with 1 M sucrose that had been pre-warmed to 37 ℃. The embryos were transferred to HM supplemented with 0.5 M sucrose for 3 minutes and then finally transferred to original HM. Subsequently, the warmed embryos were cultured for an additional 4 hours on SOF medium. At the end of this period, the embryos were evaluated for re-expansion and developmental stage progression rates. All embryos presenting no morphologically degenerating signals were considered as having survived. Embryos that changed their developmental stage during the culture period between vitrification and post warming evaluation were transferred.

Genetic characterization of fetus and animal samples
The genetic identity of the cells and animals used in this work: fibroblast of nucleus-donor animal, receptor heifer and transgenic fetus clone was determined by genetic identity examination performed with 16 microsatellite probes certified by ISAG (International Society for Animal Genetics) for cattle. The genotyping and genetic identity report of the DNA samples was issued by Geneal Diagnósticos LTDA. The confirmation of transgene cassette insertion was done by PCR using the primers: G-CSF Exon 4 Foward (5’-CCCACCTTGACACACTGCGTGG), G-CSF Exon 5 Reverse (5’-TCAGGGCTCAGCAAGGTAGCG) and pCiNeo Reverse (5’-GACAAGCTTACTTATGCTTTCCGGC). PCR (polymerase chain reaction) conditions: 1.25 mM MgCl2; 0.4 mM dNTP mix; 10 μmoles of primers and 1.5 units of Taq Polymerase (Invitrogen). Thermal cycling: 95 ℃ / 1 min; 40× (94 ℃ / 20 sec; 65 ℃ / 20 sec; 72 ℃ / 20 sec); 72 ℃ / 5 min; 12 ℃ / ∞.

Results

Bovine fibroblast transfection
The transfection of bovine fibroblasts by lipofection was successful, as can be seen in the positive control expressing the GFP, transfected with the LTX reagent and the pEF-GFP vector (Fig. 1A). Transfection with the DNA fragment containing the G-CSF and NeoR expression cassettes was also successful due to the selection response to the antibiotic G418, which eliminated 100% of the untransfected cells in 14 days (data not shown). The DNA of G418 selected cells, containing the hG-CSF/NeoR expression cassette,
was submitted to PCR amplification with primers specific for the inserted cassette, confirming the integration of the cassette into the fibroblast genome (Fig. 2, line 1).

**Synchronization of bovine fibroblast at G0/G1**

To confirm that the cells donor used in our SCNT experiments were correctly synchronized in G0/G1, we collected growing cells (60% confluence) and stationary growth phase cells (100% confluence) at different times (0 h, 60 h, 120 h). The collected cells were fixed and stained with Hoechst 33342 and analyzed by flow cytometry to separate the G0/G1 (2N, diploid genome content), S (DNA synthesis) and G2/M (mitosis, 4N genome content) populations. The results indicated that growth inhibition by contact and consequent synchronization of the G0/G1 cell population was

---

**Fig. 2. hG-CSF expression cassette PCR amplification.** Genomic DNA amplified with primers specific for transgenic hG-CSF expression cassette (A), or for endogenous G-CSF bovine gene (B). (1) Transgenic fibroblast line used as nucleus donor; (2) non-transgenic cow donor of the fibroblast line; (3) recipient heifer; (4) transgenic fetus mammary gland; (5) transgenic fetus skin; (5) transgenic fetus muscle; (7) water; (M) 1 kb Plus DNA ladder (Invitrogen). hG-CSF, human granulocyte stimulation factor; PCR, polymerase chain reaction; CSF, colony stimulating factor.

---

**Fig. 3. DNA content profile of bovine fibroblast populations according to the cell cycle stage (G0/G1, S, and G2/M) at 60% confluence (A); or 100% confluence at different post-confluence times: 0 h (B), 60 h (C), and 120 h (D).**
efficiently achieved, even within the first few hours after confluence observation (Fig. 3), indicating that the vast majority of cells used in SCNT were at the correct cell cycle stage advocated for a successful SCNT cloning event.

Production of SCNT embryos and gestation
To test our capacity of producing TG-SCNT embryos, bovine fibroblasts transfected with an enhanced GFP (eGFP) cassette, but not selected with G418, were used as a nucleus donor in SCNT procedure. This pilot test produced blastocysts expressing the eGFP reporter gene or not, depending on the incorporation of this cassette into the genome of nucleus donor cells (Fig. 1B and 1C). In a second SCNT assay, the bovine fibroblasts transfected with hG-CSF/NeoR cassette and selected with G418 were used for the reconstruction of karyoplasts, producing 103 embryos, which were transferred to 79 recipient heifers, generating two pregnancies (Table 1). The fetus of the first pregnancy was detected by ultrasonography 30 days after the TG blastocyst anovulation, but it was no longer detected in the subsequent ultrasonography at the 60th day of gestation. The second pregnancy developed until the seventh month of gestation, when a spontaneous abortion of the cloned TG fetus occurred. During this gestation, the ultrasonography and rectal palpation examination, conducted monthly, showed an anomalous number and distribution of placentomes, indicating a negative prognosis for this gestation. After the spontaneous abortion, genomic DNA was extracted from the aborted fetus tissues: mammary gland, skin and muscle, as well from blood samples of the fibroblasts of the donor cow and the recipient heifer of the TG-clone fetus. The presence of the hG-CSF/NeoR cassette was detected by PCR only in samples from the TG fetus and TG cell line, as expected (Fig. 2). The genetic identification of the DNA samples was done using 16 single sequence repeat (SSR) probes, and the identity between the nucleus donor animal and the aborted fetus was confirmed (Table 2).

Discussion
The cells expressing eGFP were used to test the SCNT parameters and protocol adopted in our laboratory previously [12], producing GFP expressing blastocysts as expected (Fig. 1B and C). Since in this test with GFP vector the G418 selection was not used, some SCNT blastocysts did not express GFP, or expressed GFP in a mosaic pattern as expected. However, with this pilot test we could proceed with the SCNT cloning using the cells transfected with the hG-CSF/NeoR cassette and selected with G418. The literature data on SCNT cloning point to the importance of the cell cycle phase during the reconstruction of embryo clones in the correct process of genome reprogramming. The correct cell-cycle synchronism between the nucleus donor cell and the MII oocyte

Table 1. Anovulation of hG-CSF blastocysts

| Embryo’s type             | Activated structures | Blastocyst rate (%) | Transferred embryos | Embryo recipients | Pregnancy detected |
|---------------------------|----------------------|---------------------|---------------------|-------------------|--------------------|
| Paternogenetic control    | 743                  | 34.8                | 259<sup>T</sup>      | -                 | -                  |
| Fresh                     | 529                  | 17.2                | 91                  | 69                | 2                  |
| Vitrified                 | 204                  | 19.6<sup>1</sup>    | 29<sup>2</sup>       | 18                | 0                  |
| Total (Fresh+vitrified)   | 733                  | 17.9                | 120                 | 87<sup>3</sup>    | 2<sup>4</sup>       |

<sup>1</sup>Blastocyst rate was calculated considering the 40 vitrified embryos.
<sup>2</sup>40 Blastocysts were vitrified, stored in N<sub>2</sub> and thawed. Twenty-nine of them (72.5%) presented re-expansion and progress in post thawing development.
<sup>3</sup>The recipient heifers were reused several times, respecting a minimum interval of one month between successive synchronizations.
<sup>4</sup>Pregnancy detection were made between 30 and 45 days after embryo anovulation. One pregnancy was absorbed between 30 and 60 days of gestation. One pregnancy produced a spontaneous abortion in the 7<sup>th</sup> month of gestation.

<sup>5</sup>Not transferred.

hG-CSF, human granulocyte stimulation factor.

Table 2. Genetic profile of 16 microsatellite markers (SSR) amplified from DNA samples extracted from the nucleus donor, transgenic fetus, and recipient heifer

| SSR marker | Nucleus donor | Transgenic fetus | Recipient heifer |
|------------|---------------|------------------|-----------------|
| AMELXY     | 356           | 356              | 356             |
| BM1818     | 266           | 266              | 264/266         |
| BM1824     | 180/182       | 180/182          | 182/192         |
| BM2113     | 139           | 139              | 141             |
| ETH10      | 213/219       | 213/219          | 209/211         |
| ETH225     | 150           | 150              | 158             |
| ETH3       | 117/125       | 117/125          | 115/117         |
| INRA005    | 123           | 123              | 121/123         |
| INRA023    | 206/210       | 206/210          | 214             |
| INRA063    | 176/178       | 176/178          | 178/182         |
| SP5113     | 145           | 145              | 139/145         |
| SP5115     | 248/252       | 248/252          | 246/248         |
| TGLA122    | 143/183       | 143/183          | 147/153         |
| TGLA126    | 115/119       | 115/119          | 115/121         |
| TGLA227    | 89/97         | 89/97            | 77              |
| TGLA53     | 162/176       | 162/176          | 160/166         |
used in the SCNT is of pivotal importance for the development of a competent clone embryo, with full potential to become a fetus that allows the birth of a healthy animal [11,16,21]. Failures in this process result in clones that are born weak and do not survive the first month of life. Considering this information, in order to be able to have a chance of successful cloning, the prerogative is that the donor nucleus cell be in the G1/G0 phase of the cell cycle [16].

Synchronization of the fibroblast culture in the G1/G0 phase (with stoppage in the cell division) can be obtained by several methods; among them serum deprivation and the inhibition of cell division by contact (confluence of 100%) are frequently used [18]. In our laboratory, we used contact inhibition as a G0/G1 synchronization method, which was shown to be an effective method to synchronize the nucleus donor cells as demonstrated by the cell cycle analysis of the confluent fibroblast cell culture. In this study, we produced 103 SNTC embryos at the blastocyst stage, 80 of them were transferred freshly to 61 recipient cows, producing two pregnancies. However, due to the low pregnancy rate observed during the dry season anovulations, probably due to the worse physical status of the recipient heifers, we decided to freeze by vitrification all GM embryos produced in the second dry season and to transfer them together in the middle of raining season, when the recipient corporal score was improved. This strategy aimed to optimize the synchronization of the recipient cows during a season with more appropriate weather condition, even knowing that the vitrification would reduce the quality and viability of the transferred embryos. This approach produced 31 expanded embryos, which, after thawing, 23 were transferred to 18 recipients (mostly transferred in pairs). This approach did not produce any positive pregnancies after 30 days of the anovulation and was no longer used later in this study. From the two pregnancies produced by the freshly transferred SCNT blastocysts, one stopped its development between the 30th and 60th day of gestation, being reabsorbed probably due to defects in the fetus development provoked by an inefficient genome reprogramming [17,19,20]. The second pregnancy developed until the 7th month of gestation, when an abortion of the fetus happened naturally. The fetus was collected as soon as it was found in the pasture, but it was in an advanced stage of decomposition. Besides its decomposition stage, we could collect samples from three tissues: mammary gland, skin and muscle. The genomic DNA was extracted from these samples and used to confirm the presence of the hG-CSF/NeoR cassette, and to confirm the genetic identity between the TG-fetus and the transfected fibroblast cell line used as the nucleus donor during the SCNT, as well as the identity with the cow from whom these fibroblasts were obtained. During the gestation of the TG fetus, the ultrasound and rectal palpation examinations showed a placenta with less placentomes than expected and with an abnormal distribution of them. This malformation of the placenta is frequently observed in SCNT-clones pregnancies, and is correlated with an abnormal or inefficient genetic reprogramming of the genome of nucleus donor cells [19,20]. These problems observed in SCNT-clone placentation is one of the major causes of the high fetal losses and low efficiency intrinsic of SCNT technique [22].

Conclusion

Although this project did not reach its initial objective of delivering live transgenic cattle expressing the hG-CSF, the knowledge produced by this work allows us to keep following to attempt the production of transgenic cattle expressing valuable biomolecules, which is so promising and strategic for Brazil.

Competing interests

No potential conflict of interest relevant to this article was reported.

Funding sources

This research was supported by Embrapa (grant 01.13.06.001.06); Brazilian National Council for Scientific and Technological Development - CNPq (grant 473833/2013–1). Bruno P. Carvalho was supported by PIBIC-CNPq scholarship.

Acknowledgements

We would thank all Farm Sucupira staff and Dr. Mauricio M. Franco for useful advising.

Availability of data and material

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Authors’ contributions

Conceptualization: Melo EO.
Data curation: Carvalho BP, Melo EO, Cunha ATM, Silva BDM, Sousa RV, Leme LO.
Formal analysis: Carvalho BP, Melo EO, Cunha ATM, Dode MAN.
Methodology: Carvalho BP, Melo EO, Cunha ATM, Silva BDM, Sousa RV, Leme LO.
Investigation: Carvalho BP, Cunha ATM, Silva BDM, Melo EO.
Writing – original draft: Melo EO.
Writing – review & editing: Carvalho BP, Cunha ATM, Silva BDM, Sousa RV, Leme LO, Dode MAN, Melo EO.

Ethics approval and consent to participate

The Ethics Committee on the Use of Animals (CEUA) of Embrapa Genetic Resources and Biotechnology approved this study.
in March of 2013 under the reference number 001/2013.

**ORCID**

Bruno P Carvalho  
https://orcid.org/0000-0003-4913-3552

Andrielle TM Cunha  
https://orcid.org/0000-0001-7272-468X

Bianca DM Silva  
https://orcid.org/0000-0003-2206-2600

Regivaldo V Sousa  
https://orcid.org/0000-0003-0252-8987

Ligiane O. Leme  
https://orcid.org/0000-0003-4818-1202

Margot AN Dode  
https://orcid.org/0000-0002-1096-0457

Eduardo O. Melo  
https://orcid.org/0000-0003-0797-920X

**Supplementary Materials**

Supplementary materials are only available online from: https://doi.org/10.5187/jast.2019.61.2.61.

**References**

1. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8:533-44.
2. Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in neutropenia. J Immunol. 2015;195:1341-9.
3. Stosser S, Schweizerhof M, Kuner R. Hematopoietic colony-stimulating factors: new players in tumor-nerve interactions. J Mol Med (Berl). 2011;89:321-9.
4. Page AV, Liles WC. Colony-stimulating factors in the prevention and management of infectious diseases. Infect Dis Clin North Am. 2011;25:803-17.
5. Melo EO, Canavessi AM, Franco MM, Rumpf R. Animal transgenesis: state of the art and applications. J Appl Genet. 2007;48:47-61.
6. Tanaka H, Tanaka Y, Shinagawa K, Yamagishi Y, Ohtaki K, Asano K. Three types of recombinant human granulocyte colony-stimulating factor have equivalent biological activities in monkeys. Cytokine. 1997;9:360-9.
7. Bertolini LR, Meade H, Lazzarotto CR, Martins LT, Tavares KC, Bertolini M, et al. The transgenic animal platform for biopharmaceutical production. Transgenic Res. 2016;25:329-43.
8. Inoue H, Nojima H, Okayama H. High efficiency transformation of Escherichia coli with plasmids. Gene. 1990;96:23-8.
9. Sambrook J. Molecular cloning: a laboratory manual. 2001. vol Accessed from. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 2001. http://nla.gov.au/nla.cat-vn2284148 Accessed 18 Mar 2019.
10. Melo EO, Sousa RV, Iguma LT, Franco MM, Rech EL, Rumpf R. Isolation of transfected fibroblast clones for use in nuclear transfer and transgene detection in cattle embryos. Genet Mol Res. 2005;4:812-21.
11. Cibelli JB, Stice SL, Golueke PJ, Kane JJ, Jerry J, Blackwell C, et al. Cloned transgenic calves produced from nonquiescent fetal fibroblasts. Science. 1998;280:1256-8.
12. Iguma LT, Lisauskas SF, Melo EO, Franco MM, Pivato I, Vianna GR, et al. Development of bovine embryos reconstructed by nuclear transfer of transfected and non-transfected adult fibroblast cells. Genet Mol Res. 2005;4:55-66.
13. Holm P, Booth PJ, Schmidt MH, Greve T, Callesen H. High bovine blastocyst development in a static in vitro production system using SOFaa medium supplemented with sodium citrate and myo-inositol with or without serum-proteins. Theriogenology. 1999;52:683-700.
14. Kuwayama M, Vajta G, Kato O, Leibo SP. Highly efficient vitrification method for cryopreservation of human oocytes. Reprod Biomed Online. 2005;11:300-8.
15. Darzynekiewicz Z. Nucleic acid analysis. Current protocols in cytometry. New York, NY: John Wiley & Sons; 1997. doi:10.1002/0471142956.cy0706s47. Accessed 18 Mar 2019
16. Verma G, Arora JS, Sethi RS, Mukhopadhyay CS, Verma R. Handmade cloning: recent advances, potential and pitfalls. J Anim Sci Biotechnol. 2015;6:43.
17. Blelloch R, Wang Z, Meissner A, Pollard S, Smith A, Jaenisch R. Reprogramming efficiency following somatic cell nuclear transfer is influenced by the differentiation and methylation state of the donor nucleus. Stem Cells. 2006;24:2007-13.
18. Tani T, Kato Y, Tsunoda Y. Direct exposure of chromosomes to nonactivated ovum cytoplasm is effective for bovine somatic cell nucleus reprogramming. Biol Reprod. 2001;64:324-30.
19. Ogura A, Inoue K, Wakayama T. Recent advancements in cloning by somatic cell nuclear transfer. Philos Trans R Soc Lond B Biol Sci. 2013;368:20110329.
20. Whitworth KM, Prather RS. Somatic cell nuclear transfer efficiency: how can it be improved through nuclear remodeling and reprogramming? Mol Reprod Dev. 2010;77:1001-15.
21. Chavatte-Palmer P, Camous S, Jammes H, Le Cleach N, Guillemot M, Lee RS. Review: Placental perturbations induce the developmental abnormalities often observed in bovine somatic cell nuclear transfer. Placenta. 2012;33 Suppl:S99-104.
22. Miglino MA, Pereira FT, Visintin JA, Garcia JM, Meirelles FV, Rumpf R, et al. Placenta in cloned cattle: structure and microvascular architecture. Theriogenology. 2007;68:604-17.
**Fig. S1.** Map of the pCiNeo/ hG-CSF cassette. hG-CSF, human granulocyte stimulation factor.